ImmunityBio, Inc. (IBRX)

$5.44

+0.04 (+0.74%)
Rating:
Recommendation:
-
Symbol IBRX
Price $5.44
Beta 0.000
Volume Avg. 1.59M
Market Cap 2.178B
Shares () -
52 Week Range 2.6-9.995
1y Target Est -
DCF Unlevered IBRX DCF ->
DCF Levered IBRX LDCF ->
ROE 127.93% Strong Buy
ROA -119.40% Strong Sell
Operating Margin -
Debt / Equity -176.19% Sell
P/E -
P/B -5.16 Strong Sell
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest IBRX news


Dr. Patrick Soon-Shiong F.A.C.S., M.Sc., FRCS (C), M.D., FACS
Healthcare
Biotechnology
NASDAQ Global Select

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.